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Abstract: 
A rapid analytical method for quantifying 17 ginsenosides in rat urine by ultra performance 
liquid chromatography (UPLC) coupled to electrospray ionization mass spectrometry (ESI-MS) 
is described. All analytes were extracted by solid-phase extraction optimized to obtain good 
recovery and quantified using digoxin as an internal standard. ESI-MS was optimized for 
different cone voltages at positive ionization mode to allow simultaneous analysis of all analytes 
in a relatively short time. Qualitative methodological considerations, including the linear range, 
precision, limit of quantification, limit of detection, recovery and sensitivity are also provided. 
 
Article: 
INTRODUCTION 
Species of Panax, including P. ginseng, P. quinquefolium L. and P. notoginseng, have been used 
for thousands of years and are now accepted as common medicinal herbs all over the world. 
More than 30 ginseng saponins (ginsenosides) have been isolated as the main biologically active 
constituents of ginseng [1,2]. There are two main maternal dammarane skeletons, 
protopanaxatriol (PPT) and protopanaxadiol (PPD) [3,4]. After oral administration, PPT 
ginsenosides are hydrolyzed to ginsenoside Rh1 and PPD ginsenosides are converted primarily to 
compound-K via stepwise cleavage of the sugar moieties by intestinal bacteria [4,5]. 
Consequently, most ginsenosides could be found in both plasma and urine of human or animal 
after administration. Some of these glucosides and their biologically active metabolites (see Fig. 
1) have been separated and analyzed by HPLC-UV, LC–MS, or GC–MS [6-9]. However, a 
method for simultaneous rapid separation and determination of ginsenosides (including Rg1, 
Rb1, Re, Rb2, Rc, Rg2) as well as secondary saponins and aglycones has yet to be described. 
Ginsengs and ginseng products consist of multiple components that may act synergistically once 
ingested in vivo. Thus, in order to clarify the pharmacological and toxicological properties of 
ginsengs, it is important to monitor active constituents as many as possible when profiling the 
ginsenoside composition of plant, product and biofluid. 
 
Figure 1: Chemical structures and m/z values of ginsenosides and their main degradation products in addition to the 
cone voltage setting according to m/z [M + Na]. 
 
Since many ginsenosides are of similar polarity and not easy to be chemically derivatized, it is 
difficult to detect multi-ginsenosides simultaneously by HPLC-UV or GC–MS. Consequently, 
LC–MS is becoming the most suitable and convenient instrument for ginsenoside analysis [8]. 
However, multi-components analysis requires better separation which often results in longer 
retention times and consumption of more mobile phase. The recently developed ultra 
performance liquid chromatography (UPLC) system offers a solution to this problem. The 
ACQUITY UPLC instrument (Waters Corporation, USA) is a commercially available UPLC 
system with full instrument modifications, including advancements in the solvent delivery 
module and new column technology, which utilizes pressure-tolerant 1.7 μm hybrid particles 
containing a bridged ethylsiloxane/silica structure allowing the Acquity to run routinely at 
pressures up to 15,000 psi [10]. The Acquity sample manager has also been modified to permit 
injection of as little as 1 μL using a needle-in-needle probe [10]. The combination of these 
technological developments produces increased sensitivity, improved peak resolution, and a 
significant reduction in analysis time compatible with rapid throughput [11,12]. 
 
We have established a rapid UPLC–MS quantification method for simultaneous multi-
component analysis of ginsenosides and their metabolites in rat urine. The precision, linearity, 
limit of quantification (LOQ), limit of detection (LOD), recovery and sensitivity of the analytical 
method have been systematically evaluated. Effects of the solid-phase extraction process, UPLC 
elution, and mass conditions on ginsenoside separation and detection in spiked standards and 
urine samples are also investigated. 
 
EXPERIMENTAL PROCEDURES 
Materials and reagents 
The internal standard, digoxin, and Rg1, Rb1, and Re ginsenosides were obtained from the 
National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). 
Rf, Rb2, Rg2(S), Rg2(R), Rc, Rd, Rh1, Rg3(S), Rg3(R), C-K, F1, F2, PPT and PPD were 
obtained from Wuhu DELTA Co. (Anhui, China) and Sanqi Research Institute of Wenshan 
Prefecture (Yunnan, China). Total ginsenosides were purchased from Hangzhou Greensky 
Biological Tech. Co. Ltd. HPLC-grade methanol and acetonitrile were purchased from Merck 
(New Jersey, USA). Water used in the experiments was generated by a Milli-Q Ultra-pure water 
system (Millipore, Billerica, USA). Other chemicals (analytical grade) were purchased from 
Sigma (St. Louis, MO, USA). OasisTM HLB, 1cc, solid-phase extraction (SPE) cartridges and 
Manifold for Extraction Cartridge were purchased from Waters Co. (Milford, MA, USA). 
 
Apparatus and operating conditions 
Chromatographic separation was carried out on an ACQUITY UPLCTM system from Waters Co. 
using an ACQUITY UPLCTM BEH C18 column (50 mm × 2.1 mm, 1.7 μm particle size). The 
column temperature was 40 °C, the flow rate was 0.35 mL min−1, and the injection volume was 
5 μL. The mobile phase consisted of water (A) and acetonitrile (B). The initial composition was 
95% A and 5% B. A gradient elution was performed where phase B increased linearly from 0 to 
50% over the first 6 min, then increased to 90% over 3 min, then increased to 95% in 1 min, was 
maintained for 2 min, and finally returned to the initial composition in 1 min. The column was 
re-equilibrated for another 1 min before the next injection. 
 
Mass spectrometry was carried out on a Micromass–ZQ mass spectrometer (Waters Co.) using 
the positive electrospray ionization (ESI) mode (data analysis software MassLynx V4.1). 
Nitrogen was used as the nebulizer, desolvation and cone gas. The mass spectrometer was 
operated at a capillary voltage of 3.5 kV, desolvation gas flow of 700 L h−1, cone gas flow of 
50 L h−1, desolvation temperature of 350 °C, source temperature of 120 °C, LM resolution of 
15.2, HM resolution of 14.5, RF of 0 V, ion energy of 0.5 V, and multiplier voltage of 650 V. In 
the selected ion recording (SIR) mode, the cone voltage was set to different voltages according to 
different m/z (see Fig. 1). 
 
Sample collection and preparation 
Eight male Sprague-Dawley rats weighing 200 ± 20 g (8 weeks old) were purchased from 
Shanghai SLAC Laboratory Animal Co. Ltd. (Shanghai, China) and individually housed in 
metabolic cages. Rats received total ginsenosides orally at a daily dose of 100 mg kg−1 from days 
1 to 13. Blank 24-h urine samples were collected on day 0. Test urine samples were collected 
after ginsenoside administration on days 7, 10, and 13. The fresh urine samples were 
immediately centrifuged at 3500 rpm for 10 min at room temperature in order to remove particle 
contaminants, and then supernatants were stored at −20 °C pending analysis. The urine volume 
and body weight of each rat were recorded over the entire course of the experiment. 
 
HLB solid-phase extraction cartridges were equilibrated with 1 mL of methanol and 2 mL of 
water, then 700 μL of urine supernatant with 50 μL of internal standard solution (1 μg mL−1) was 
passed through the cartridge under gentle vacuum. The cartridges were then washed five times 
with water and dried. Finally, the cartridge was eluted twice with 0.2 mL of 95% methanol (a 
mixture of 95% methanol and 5% of water) then mixed. After centrifugation at 20,000 × g for 
10 min at 4 °C, 5 μL of the supernatant was injected into the UPLC/ESI-MS. 
 
Method validation 
Stock solutions for the 17 analytes were prepared separately in DMSO (dimethyl sulfoxide). 
Digoxin stock solution was prepared in pyridine. Working solutions were prepared in methanol 
by mixing known amount of all the compounds together. To simulate real sample analysis, a 
series of standard solutions including quality control (QC) samples were prepared using blank rat 
urine specimen spiked with known serial amounts of the 17 analytes and then extracted by SPE 
(prepared as described in Section 2.3) prior to UPLC–MS analysis (Table 1). The limits of 
detection and quantitation for each compound were estimated by the low concentration standard 
solutions mentioned above and the dilutions, when the target signal peak's signal-to-noise (S/N) 
≥ 3 and ≥ 9. Based on the LOQ level, concentration scale and linear regression equation was 
established, where the regression coefficient (r2) of each analyte's linear regression equation 
should be >0.99. 
 
Table 1: Linearity for each component LOD and LOQ of spiked urine 
Compound Linear range (μg mL−1)a n r2b LOD (ng mL−1) LOQ (ng mL−1) 
Rb1 0.01–1 6 0.997541 2 8 
Rb2 0.01–1 6 0.997516 3 10 
Rc 0.01–1 6 0.996406 4 12 
Rd 0.01–1 6 0.998446 3 10 
Re 0.02–2 6 0.99812 8 20 
Rg1 0.02–2 6 0.998321 6 18 
Rf 0.02–2 6 0.996542 8 20 
Rg2(S) 0.05–5 6 0.997618 16 50 
Rg2(R) 0.05–5 6 0.997818 15 45 
F2 0.02–2 6 0.999299 8 20 
Rg3(S) 0.02–2 6 0.998446 6 18 
Rg3(R) 0.02–2 6 0.998848 8 20 
Rh1 0.05–5 6 0.998095 15 45 
F1 0.02–2 6 0.993589 8 20 
C-K 0.05–5 6 0.995013 16 50 
PPT 0.05–5 6 0.99955 18 55 
PPD 0.05–5 6 0.998898 16 50 
aEach standard stock solution of test compounds was carefully prepared in DMSO (1 mg mL−1) and stored at −4 °C. 
bRegression coefficients were calculated for linearity ranging at the concentration listed here. 
 
In order to discover possible interference among analytes, specificity was determined by 
comparing QC samples with blank rat urine that had undergone the same pretreatment and 
analysis. Precision was calculated as the relative standard deviation (R.S.D.). Intraday precision 
and accuracy were evaluated by analyzing triplicates of three QC samples (low, middle, and high 
concentrations) over the course of a single day (Table 2). Interday variation was evaluated on the 
same QC samples on three different days. The freeze–thaw stability study was also carried out 
every 7 days for a month on the same three QC samples stored at −20 °C in the dark. As 
biological specimen analysis, all these R.S.D. should be <15% [8]. 
 
Table 2: Recovery and precision (R.S.D.) (n = 3) 
Compound Spiked level (ng mL−1) Recovery (%)  Intraday (ng mL−1)  Interday (ng mL−1) 
  Mean R.S.D.  Mean R.S.D. (%)  Mean R.S.D. (%) 
Rb1 10.3 90.6 8.8  9.4 9.6  9.5 10.8 
103.2 92.1 7.2  103.7 8.2  106.8 11.3 
1032.0 94.5 5.2  1028.5 6.1  983.1 9.6 
   
Rb2 10.6 89.4 7.9  9.6 10.8  9.2 9.8 
106.4 93.1 6.6  96.4 9.7  93.7 10.4 
1064.0 93.9 5.0  995.3 9.1  978.0 9.5 
   
Rc 10.2 92.5 7.3  10.2             11.2  10.5 10.6 
102.4 94.0 5.6  104.6 9.9  102.8 10.3 
1024.0 93.2 6.7  986.1 8.6  987.4 9.4 
   
Rd 10.4 85.1 10.2  10.5 9.0  9.7 9.2 
104.3 82.9 9.4  92.8 9.6  95.0 8.7 
1043.0 84.7 7.9  973.0 9.4  1032.8 9.4 
   
Re 20.5 78.3 9.2  18.5 9.5  19.4 10.8 
205.3 77.0 8.3  209.3 9.7  207.6 9.1 
2052.0 80.4 6.9  2016.8 9.0  1988.7 9.3 
   
Rg1 20.4 75.6 6.4  21.6 8.6  19.8 10.8 
204.3 75.1 7.1  195.3 9.4  208.9 9.2 
2043.0 76.5 5.8  2076.9 7.8  2058.4 8.7 
   
Rf 20.2 77.6 7.0  19.6 8.6  19.8 11.8 
202.3 76.0 8.9  208.6 8.2  195.7 8.9 
2023.0 76.3 8.6  2043.9 7.9  2067.2 10.3 
   
Rg2(S) 50.4 81.5 9.6  47.8 10.3  50.4 9.9 
503.6 82.8 8.1  505.4 9.4  506.1 8.6 
5036.0 84.3 8.4  5060.1 9.0  5078.2 9.5 
   
Rg2(R) 50.6 82.6 9.9  48.1 9.9  48.7 10.5 
505.7 85.4 8.6  486.4 8.2  492.3 9.7 
5057.0 84.2 7.9  4957.2 7.8  5078.6 8.4 
 
 
  
F2 20.4 83.1 6.2  20.7 11.0  20.4 10.3 
203.8 85.8 5.4  195.4 9.7  208.9 10.1 
2038.0 82.6 3.0  2061.0 8.9  1992.6 9.0 
   
Rg3(S) 20.6 76.4 9.3  20.7 10.8  19.2 11.4 
206.2 75.3 7.6  185.6 9.3  190.8 10.7 
2062.0 75.6 7.2  1953.2 9.5  2037.9 9.6 
   
Rg3(R) 20.4 81.8 6.4  21.8 9.8  20.5 10.6 
203.7 82.3 5.8  186.3 9.0  194.6 9.4 
2037.0 83.4 4.7  2052.4 7.6  2089.5 8.9 
   
Rh1 50.8 82.5 8.0  49.6 9.1  51.7 9.7 
508.3 83.3 6.2  514.3 6.8  506.2 8.1 
5083.0 86.9 6.5  4962.7 5.7  5067.3 8.5 
   
F1 20.3 82.1 7.3  20.5 10.2  19.7 9.8 
202.6 85.4 5.0  191.4 9.4  208.9 9.7 
2026.0 83.6 6.8  1994.9 8.0  2013.6 9.2 
   
C–K 50.4 77.4 11.6  53.1 8.6  50.1 10.6 
503.7 75.0 8.7  510.8 8.9  490.5 9.7 
5037.0 79.7 8.3  4990.5 8.1  5027.8 6.8 
   
PPT 50.4 78.4 8.7  48.6 9.7  51.7 11.8 
504.0 76.3 7.4  488.3 8.3  506.2 8.8 
5040.0 75.1 6.1  4903.7 7.2  5068.1 7.9 
   
PPD 50.3 75.4 6.7  52.8 9.9  49.3 10.6 
503.1 75.5 5.3  492.4 8.6  506.9 8.6 
5031.0 74.9 5.8  4937.0 7.5  5061.7 8.4 
 
Extraction recovery was evaluated for the same QC samples by comparing peak area of interest 
from SPE pretreated sample with the same concentration of matrix-matched solutions. The QC 
samples were also used to further optimize the extraction method. 
 
RESULTS AND DISCUSSION 
UPLC/MS conditions 
The ACQUITY UPLC provided a rapid, high resolution, economical method for multi-
ginsenoside analysis (Fig. 2). Relative to HPLC–MS methods described in previous studies 
[13,14], UPLC reduced analytical time by at least 75%, thus significantly conserving eluent. All 
constituents presented good peak capacity with a 14-min gradient. In theory, the UPLC column 
requires a higher flow rate (above 0.6 mL min−1) to gain super separation and the electrospray 
source can accommodate flow rates up to 1.0 mL min−1. However, flow into the ion source of 
mass should be below 0.2 mL min−1 to increase ionization efficiency and ameliorate ion 
suppression which significantly influences analyte sensitivity. In order to obtain greater 
sensitivity and higher resolution simultaneously, we tested several different flow rate conditions 
before deciding on a flow rate of 0.35 mL min−1 as the best compromise. Most ginsenosides 
possessed similar polarity and showed almost dull peaks by isocratic elution, while gradient 
elution resulted in better separation and lower LOQ. During gradient elution optimization, we 
found that hydrophilic substances eluted early and if the gradient changed too rapidly, Rg1 and 
Re were easily buried by other hydrophilic impurities in urine. Therefore, we selected a gentle 
gradient and short analysis time in order to achieve effective elution and minimize matrix effects. 
Formic acid was added to the mobile phase at 0.1%, but it greatly reduced peak signal response 
with little enhancement of separation. Therefore pure water generated by Milli-Q and acetonitrile 
were chosen for the mobile phase. 
 
 
Figure 2: Blank and spiked urine sample total ion chromatograms (TIC) detected by UPLC–MS: (A) blank urine 
specimen; (B) spiked urine specimen (PPT and PPD 2.0 μg mL−1, others 0.2 μg mL−1). 
 
In preliminary tests, standard substances were tuned at positive and negative modes directly in 
ZQ Mass with mobile phase. For all compounds, [M + Na]+, [M + K]+, and [M − H]− were found 
in the positive and negative ion spectra, respectively, but [M + Na]+ was the most abundant, so 
the adduct ion of [M + Na]+ was selected as the target m/z. For electrospray mass spectrometry, a 
flow rate of 0.35 mL min−1 showed better resolution but more interference by solvents, so the 
desolvation gas flow was set at 700 L h−1, cone gas flow at 50 L h−1, and desolvation temperature 
at 350 °C to remove redundant solvents. We had tried the other ionization mode atmospheric 
pressure chemical ionization (APCI), of the instrument and found that, although APCI could 
accommodate a higher flow (<2.0 mL min−1) the intensive ionization style did not fit for the 
current simultaneous analysis of ginsenosides. Most of the analytes are saponins which have the 
instable glucosidic bonds connected with different glycons, as seen in Fig. 1. APCI source 
provides a higher temperature and more intense ionization leading to the glucosidic bonds 
cleavage and therefore failure of simultaneous quantification of ginsenosides with different 
glycons. Such an ionization mode is more suitable for low molecular weight compounds with 
non-polarity, which, in this case, do not represent the characteristics of ginsenosides. Therefore, 
the ESI ionization mode was chosen for this study. In order to gain strong quasi-molecular ion 
response in spectrum (Fig. 1), cone voltage was optimized to values ranging from 75 to 120 V 
according to the different m/z of the analytes, which ranged from 483.6 to 1131.8. 
 
Sample preparation 
Interference from endogenous biochemical compounds presents a problem for analysis of 
biological specimens. Solid-phase extraction is a rapid, convenient sample treatment method for 
detecting metabolites in plasma and urine [15]. We compared the absolute extraction recovery of 
C8 (Alltech Co., USA), C18, and HLB SPE cartridges with the same matrix-matched samples. As 
seen in Fig. 3, extraction recovery of Rg1 and Re was better with C8 than others. However, 
recovery of the other compounds, including the internal standard, was significantly greater with 
HLB and C18 than C8 cartridges. We assumed that the discrepancy reflected the polarity affinity 
of different chemical bonded phases and functional groups. For most target compounds, HLB 
cartridges provided both high recovery with less discrimination and better reproducibility under 
batch operations due to hydrophile–lipophile balanced packing material. Therefore, HLB SPE 
cartridges were chosen for this study. If the focus of study is analysis of origin saponins, such as 
Re and Rg1, the C8 cartridge is a good choice for sample treatment. 
 
 
Figure 3: Comparison of the extraction recovery of the 17 analytes spiked in blank urine after extraction with HLB, 
C18 and C8 SPE cartridge. 
 
Loading speed was important for extraction, hence we investigated sample loading times ranging 
from 5 to 60 s. For all substances, extraction efficiency was similar when loading times were 
≥40 s. Thus, we selected 40 s. Methanol concentrations ranging from 80% (a mixture of 80% 
methanol and 20% water) to 100% were tested for the final elution. After weighing the efficiency 
for each substance, 95% methanol was chosen as the eluent for the validation study. 
 
Method validation 
As shown in Fig. 2, blank urine did not produce interference under our working conditions. Both 
the analytes and internal standard could be detected on their own selected ion chromatograms 
without mutual interference (Fig. 4). Linearity of response was evaluated using matrix-matched 
standards ranging from 0.01 to 1 μg mL−1 for Rb1, Rb2, Rc and Rd; 0.02 to 2 μg mL−1 for Re, 
Rg1, F1, F2, Rg3(S), Rf and Rg3(R); 0.05 to 5 μg mL−1 for Rg2(S), Rg2(R), Rh1, C-K, PPT and 
PPD as listed in Table 1. Calibration curves for each test compound were adjusted using the 
internal standard. The regression coefficients of determination (r2) generally approached 1.000 
(≥0.99) for all compounds tested. We determined the LOD and LOQ for each compound by 
analyzing signal-to-noise ratios ≥3 and ≥9. The S/N ratio calculation was carried out displaying 
the peak-to-peak values by Masslynx software. Occasionally, the actual quantification limit was 
less than the lowest spiked concentration, which had a higher S/N value. The lowest spiked 
concentration was used as the quantification limit in these instances. 
 
 
Figure 4: SIR chromatograms of blank urine specimen spiked with the 17 analytes (PPT and PPD 2.0 μg mL−1, 
others 0.2 μg mL−1). (A) m/z from 483.8 to 803.8; (B) m/z from 807.9 to 1131.8. 
Recovery, intraday and interday precision were evaluated by analyzing triplicate samples of 
three concentrations of rat urine, as shown in Table 2. Recovery, intraday and interday 
performance, expressed as R.S.D., was less than 12% (the acceptance criteria is <15%) for all 
concentrations within the standard curve [8]. Similar results were obtained by two different 
operators. 
 
The freeze/thaw stability of rat urine samples was studied by storing urine spiked with known 
amounts of each of the 17 standard substances at −20 °C. Samples were thawed at 37 °C and 
analyzed. The R.S.D. of the 17 analytes were less than 12% (the acceptance criteria is <15%) 
during freeze/thaw tests, indicating the substances were stable when stored at −20 °C then 
thawed at 37 °C. 
 
Application of the method 
Urine samples collected from rats orally administered total ginsenosides were analyzed using the 
method described above. As expected, all 17 ginsenosides were detected in all samples. A typical 
chromatogram is displayed in Fig. 5. Excretion of the 17 ginsenosides over a 24 h period was 
quantified on days 7, 10, and 13 (Fig. 6). The results demonstrate that our method can be applied 
for the detection and quantification of ginsenosides and their metabolites. 
 
 
Figure 5: SIR chromatograms of 24-h urine sample after administration of the total ginsenosides. (A) m/z from 
483.8 to 803.8; (B) m/z from 807.9 to 1131.8. 
 
Figure 6: 24 h excretion quantity (μg) of 17 ginsenosides found in urine samples from total ginsenosides treated rats 
(n = 8). 
 
CONCLUSIONS 
A UPLC–MS method for rapid separation and quantification of 17 ginsenosides has been 
established and used to analyze rat urine. Target analytes were isolated by HLB solid-phase 
extraction, analyzed simultaneously, and precisely quantified using an internal standard. 
Compared to other methods, this procedure requires shorter analysis time and less solvent, while 
providing at least comparable sensitivity. We have shown that UPLC–MS technology is superior 
for characterizing and quantifying complex ginsenosides, secondary glucosides and aglycones. 
With SPE pretreatment, this method could be used to profile ginsenosides and their metabolites 
in ginseng pharmacokinetic and metabolism studies. 
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